Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product
-
- STATUS
- Recruiting
-
- End date
- Mar 20, 2024
-
- participants needed
- 172
-
- sponsor
- Jun Zhu
Summary
Title: Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy Subjects for the Development of Cellular Immunotherapy Product
- Background
CAR-T therapies are being developed that utilize modified immune cells to fight tumors. 'Off-the-shelf' allogeneic CAR-T technology has better efficacy and more promising clinical applications. Investigators want to use the cells of healthy subjects to perform the studies. To accomplish this, they are collecting PBMCs through apheresis.
- Objectives
To collect PBMCs from healthy subjects for product development for cell Immunotherapies.
Description
- Background
Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells from donors has many potential advantages over autologous approaches, such as the immediate availability of cryopreserved batches for patient treatment, possible standardization of the CAR-T cell product, time for multiple cell modifications, redosing or combination of CAR T cells directed against different targets, and decreased cost using an industrialized process. The T cells currently used for CAR-T cell manufacturing are mainly derived from peripheral blood mono-nuclear cells (PBMCs) .The manufacture of allogeneic CAR T cells from PBMCs collected from healthy donors is associated with the ability to make multiple vials from a single apheresis product. Allogeneic CAR T cells are created from healthy donors, they are generated from immune cells that have not been impacted by the immune effects of cancer or by exposure to chemotherapeutic agents, in contrast to autologous T cells from patients. The selection of donors on the basis of their immune characteristics is likely to be a key factor in decreasing the heterogeneity of the final cell product
- Objectives
-
- To produce allogeneic CAR T cells with different targets and other cell products by using PBMCs from healthy subjects.
- To develop and optimize the methodology for the response or quality determination of cell Immunotherapy products.
- Design
All subjects are required to sign a written informed consent form for the study. After the signing of informed consent form, participants will be screened with a series of vital signs, physical examinations and laboratory tests. Demographic data and medical history of the subjects will also be documented. In addition, 30 mL peripheral venous blood sample will be collected to evaluate the biological characteristics of each subject. Participants will undergo a routine blood test within 24 hours before the apheresis to reconfirm their eligibility and 3-5 mL blood samples are to be drawn for the development of detection methods of cell-based immunotherapy. Subjects who meet all the inclusion criteria and do not meet any exclusion criteria are qualified to donate peripheral blood mono-nuclear cells (PBMCs) by means of apheresis. 610[9] of cells for each healthy person are preferred. 172 healthy subjects are to be enrolled through the whole study.
Details
| Condition | Healthy Subject |
|---|---|
| Treatment | Peripheral blood mononuclear cell apheresis |
| Clinical Study Identifier | NCT04295096 |
| Sponsor | Jun Zhu |
| Last Modified on | 1 March 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer